Andreas H Jacobs Selected Research

alovudine

1/2022	Voxel-Based Analysis of the Relation of 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) PET and Diffusion-Weighted (DW) MR Signals in Subcutaneous Tumor Xenografts Does Not Reveal a Direct Spatial Relation of These Two Parameters.
1/2021	Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma.
1/2018	Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model.
1/2018	3'-Deoxy-3'-[18F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models.
1/2017	Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.
12/2016	Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
1/2014	An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas.
1/2013	Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
6/2011	[18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas.
12/2009	Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas H Jacobs Research Topics

Disease

41	Neoplasms (Cancer) 06/2022 - 10/2003
36	Glioma (Gliomas) 06/2022 - 02/2003
11	Glioblastoma (Glioblastoma Multiforme) 06/2022 - 10/2003
11	Neuroinflammatory Diseases 01/2022 - 05/2012
7	Brain Neoplasms (Brain Tumor) 06/2022 - 11/2004
5	Stroke (Strokes) 01/2022 - 11/2015
5	Infections 01/2021 - 02/2003
5	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 03/2004
5	Parkinson Disease (Parkinson's Disease) 09/2019 - 03/2005
4	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2008
4	Ischemia 01/2022 - 11/2020
4	Ischemic Stroke 01/2020 - 08/2004
3	Inflammation (Inflammations) 01/2022 - 01/2017
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 03/2004
3	Infarction (Infarctions) 01/2020 - 08/2004
3	Disease Progression 04/2015 - 02/2010
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2018
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 11/2020 - 11/2015
2	Multiple Sclerosis 01/2019 - 05/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2011 - 01/2008
2	Insulin Resistance 11/2006 - 03/2004
1	Urinary Bladder Neoplasms (Bladder Cancer) 04/2022
1	Acute Kidney Injury (Acute Renal Failure) 04/2022
1	Breast Neoplasms (Breast Cancer) 12/2021
1	Meningioma (Meningiomas) 12/2020
1	Gliosis 11/2020
1	Primary angiitis of the central nervous system 01/2020
1	Proteostasis Deficiencies 12/2019
1	Cognitive Dysfunction 07/2019
1	Dementia (Dementias) 07/2019
1	Delirium 07/2019
1	Deglutition Disorders (Dysphagia) 07/2019

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 06/2022 - 05/2012
11	alovudineIBA 01/2022 - 12/2005
11	Biomarkers (Surrogate Marker)IBA 12/2021 - 05/2012
11	N,N- diethyl- 2- (2- (4- (2- fluoroethoxy)phenyl)- 5,7- dimethylpyrazolo(1,5- a)pyrimidin- 3- yl)acetamideIBA 01/2021 - 05/2012
9	Amino Acids FDA Link 06/2022 - 11/2004
8	Methionine (L-Methionine)FDA Link 01/2017 - 11/2004
7	Biological ProductsIBA 12/2019 - 10/2003
7	Glucose (Dextrose)FDA LinkGeneric 06/2014 - 12/2005
6	Pharmaceutical PreparationsIBA 01/2022 - 06/2010
6	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 05/2006
6	GadoliniumIBA 05/2015 - 12/2005
5	acetamideIBA 01/2022 - 12/2013
5	ThymidineIBA 01/2018 - 01/2008
4	Therapeutic UsesIBA 01/2021 - 10/2003
4	Matrix Metalloproteinases (MMPs)IBA 11/2020 - 11/2015
4	Ganciclovir (Cytovene)FDA LinkGeneric 11/2007 - 02/2003
3	LigandsIBA 01/2017 - 11/2009
3	ErbB Receptors (EGF Receptor)IBA 05/2011 - 11/2005
3	Thymidine KinaseIBA 11/2007 - 03/2005
2	gamma-glutamylaminomethylsulfonic acid (GAMS)IBA 06/2022 - 01/2020
2	pyrimidineIBA 01/2022 - 01/2022
2	Indicators and Reagents (Reagents)IBA 01/2022 - 07/2012
2	Macrophage Colony-Stimulating FactorIBA 01/2022 - 01/2022
2	thymidine kinase 1IBA 01/2021 - 01/2017
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 01/2016
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2020 - 12/2005
2	Thymidylate SynthaseIBA 01/2018 - 12/2016
2	Caspase 3 (Caspase-3)IBA 12/2016 - 06/2014
2	Dopamine (Intropin)FDA LinkGeneric 01/2016 - 10/2006
2	EnzymesIBA 11/2015 - 05/2015
2	Pentetic Acid (DTPA)FDA LinkGeneric 05/2015 - 12/2011
2	AcidsIBA 05/2015 - 01/2010
2	Tyrosine (L-Tyrosine)FDA Link 07/2013 - 03/2013
2	Small Interfering RNA (siRNA)IBA 03/2013 - 11/2005
2	Pioglitazone (Actos)FDA Link 01/2013 - 11/2006
2	Gadolinium DTPA (Magnevist)FDA Link 12/2011 - 01/2010
2	Green Fluorescent ProteinsIBA 06/2011 - 02/2003
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2011 - 01/2008
2	GuanineIBA 11/2007 - 07/2007
2	9-(4-fluoro-3-hydroxymethylbutyl)guanineIBA 07/2007 - 02/2007
2	ProdrugsIBA 02/2007 - 02/2003
1	AminesIBA 01/2022
1	PLX5622IBA 01/2022
1	RadiopharmaceuticalsIBA 12/2021
1	Thiobarbituric Acid Reactive SubstancesIBA 01/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2021
1	3,4-dihydroxyphenylethanol (hydroxytyrosol)IBA 01/2021
1	VC701 compoundIBA 01/2021
1	C-Reactive ProteinIBA 12/2020
1	HLA-DR Antigens (HLA-DR)IBA 01/2020
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020
1	ethyl tyrosine esterIBA 01/2020
1	Ion Channels (Ion Channel)IBA 09/2019
1	Purinergic P2X7 ReceptorsIBA 09/2019
1	Adenosine Triphosphate (ATP)IBA 09/2019
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 07/2019
1	Memantine (Namenda)FDA Link 07/2019

Therapy/Procedure

32	Therapeutics 06/2022 - 04/2005
6	Drug Therapy (Chemotherapy) 01/2020 - 05/2006
4	Aftercare (After-Treatment) 01/2016 - 04/2005
4	Radiotherapy 03/2013 - 01/2008
1	Precision Medicine 12/2021
1	Mediterranean Diet 01/2021
1	Immunomodulation 01/2021
1	Artificial Respiration (Mechanical Ventilation) 12/2020
1	Immunotherapy 01/2020
1	Combined Modality Therapy 10/2019
1	Length of Stay 07/2019